eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
SCImago Journal & Country Rank

3/2022
vol. 14
 
Share:
Share:
more
 
 
abstract:
Original paper

Feasibility and efficacy of endoscopic ultrasound-guided iodine-125 seed implantation in inoperable ampullary carcinoma: initial clinical experience

Tingting Cui
1, 2
,
Lianqiang Han
2, 3
,
Nianjun Xiao
1, 4
,
Fang Liu
2
,
Wen Li
2

1.
Department of Gastroenterology and Hepatology, Medical School of Chinese PLA, Beijing, China
2.
Department of Gastroenterology and Hepatology, the First Medical Center, Chinese PLA General Hospital, Beijing, China
3.
School of Medicine, Nankai University, Tianjin, China
4.
Department of Gastroenterology, Air Force Medical Center, Beijing, China
J Contemp Brachytherapy 2022; 14, 3: 233-240
Online publish date: 2022/05/10
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Purpose
The objectives of the present study were to evaluate the feasibility, safety, and efficacy of endoscopic ultrasound (EUS)-guided iodine-125 (125I) seed implantation in ampullary carcinoma (AC).

Material and methods
From January 2011 to June 2020, 13 patients were selected for this retrospective study. Thirteen tumors (27.46 ±12.07 mm) were treated with EUS-guided 125I seed implantation in 29 sessions. We evaluated the therapeutic efficacy, adverse effects, and overall survival (OS) time.

Results
Complete response (CR) was observed in one tumor in 6 months. Partial response (PR) was detected in two target tumors in 3 months, seven in 6 months, seven in 9 months, and six in 12 months. Good periods of survival were observed. The median OS was 35 months, 95% confidence interval (95% CI) was 8.97 to 61.03 months. The 1-, 2-, and 5-year OS rates were 100%, 67.5%, and 11.3%, respectively. There were no procedure-related deaths or serious adverse events. Transient abdominal pain (5 cases, 17.2%), abdominal distension and loss of appetite (3 cases, 10.3%), and seed migration (1 case, 3.4%) were observed, respectively.

Conclusions
In selected patients with inoperable AC, EUS-guided 125I seed implantation is feasible and safe with favorable local control efficacy and OS.

keywords:

endoscopic ultrasound, adenocarcinoma, ampullary, brachytherapy

 
Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.